Rigel Pharmaceuticals, Inc. – NASDAQ:RIGL
Rigel Pharmaceuticals stock price today
$38.52
+22.01
+133.45%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 17 hours
Rigel Pharmaceuticals stock price monthly change
+65.33%
month
Rigel Pharmaceuticals stock price quarterly change
+65.33%
quarter
Rigel Pharmaceuticals stock price yearly change
+1022.45%
year
Rigel Pharmaceuticals key metrics
Market Cap | 289.26M |
Enterprise value | 189.70M |
P/E | -3.42 |
EV/Sales | 1.57 |
EV/EBITDA | -3.52 |
Price/Sales | 1.76 |
Price/Book | -15.57 |
PEG ratio | 0.01 |
EPS | -0.11 |
Revenue | 120.34M |
EBITDA | -11.86M |
Income | -19.80M |
Revenue Q/Q | 13.28% |
Revenue Y/Y | -7.12% |
Profit margin | -48.71% |
Oper. margin | -46.2% |
Gross margin | 98.55% |
EBIT margin | -46.2% |
EBITDA margin | -9.86% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeRigel Pharmaceuticals stock price history
Rigel Pharmaceuticals stock forecast
Rigel Pharmaceuticals financial statements
| Jun 2023 | 26.88M | -6.6M | -24.55% |
|---|---|---|---|
| Sep 2023 | 28.13M | -5.69M | -20.23% |
| Dec 2023 | 35.79M | 737K | 2.06% |
| Mar 2024 | 29.53M | -8.24M | -27.92% |
| Mar 2024 | 29.53M | -8.24M | -27.92% |
|---|---|---|---|
| Sep 2025 | 50.06M | 2.61M | 5.23% |
| Oct 2025 | 49.34M | 15.76M | 31.96% |
| Dec 2025 | 50.81M | 40.29M | 79.29% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 117091000 | 145.20M | 124.01% |
|---|---|---|---|
| Sep 2023 | 115324000 | 147.15M | 127.6% |
| Dec 2023 | 117225000 | 145.86M | 124.44% |
| Mar 2024 | 126519000 | 158.19M | 125.03% |
| Jun 2023 | 5.93M | 2.97M | -373K |
|---|---|---|---|
| Sep 2023 | -1.35M | -1.17M | -869K |
| Dec 2023 | -6.24M | -6.87M | 486K |
| Mar 2024 | -5.01M | 313K | -2.51M |
Rigel Pharmaceuticals alternative data
| Sep 2023 | 155 |
|---|---|
| Oct 2023 | 155 |
| Nov 2023 | 155 |
| Dec 2023 | 155 |
| Jan 2024 | 155 |
| Feb 2024 | 155 |
| Mar 2024 | 147 |
| Apr 2024 | 147 |
| May 2024 | 147 |
| Jun 2024 | 147 |
| Jul 2024 | 147 |
Rigel Pharmaceuticals other data
21.57%
-41.75%
of RIGL is owned by hedge funds
75
-44
37.18M
-72.25M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 0 | 80041 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | SANTOS DAVID A officer: EVP, Chi.. | Common Stock | 8,918 | $1.14 | $10,167 | ||
Sale | SCHORNO DEAN L officer: EVP & Chief Financial .. | Common Stock | 7,027 | $1.14 | $8,011 | ||
Sale | RODRIGUEZ RAUL R director, officer.. | Common Stock | 30,545 | $1.14 | $34,821 | ||
Sale | SANTOS DAVID A officer: EVP, Chi.. | Common Stock | 5,601 | $1.13 | $6,329 | ||
Sale | SCHORNO DEAN L officer: EVP & Chief Financial .. | Common Stock | 5,601 | $1.13 | $6,329 | ||
Sale | RODRIGUEZ RAUL R director, officer.. | Common Stock | 22,349 | $1.13 | $25,254 | ||
Sale | RODRIGUEZ RAUL R director, officer.. | Common Stock | 20,340 | $1.75 | $35,595 | ||
Sale | DUMMER WOLFGANG officer: EVP & CMO | Common Stock | 5,389 | $1.66 | $8,946 | ||
Sale | SCHORNO DEAN L officer: EVP & Chief Financial .. | Common Stock | 5,389 | $1.66 | $8,946 | ||
Sale | SANTOS DAVID A officer: EVP, Chi.. | Common Stock | 5,388 | $1.66 | $8,944 |
| Patent |
|---|
Application Filling date: 4 Feb 2022 Issue date: 11 Aug 2022 |
Grant Filling date: 4 Sep 2020 Issue date: 9 Aug 2022 |
Application Filling date: 10 Dec 2021 Issue date: 14 Jul 2022 |
Grant Filling date: 16 Sep 2020 Issue date: 5 Jul 2022 |
Grant Filling date: 16 Sep 2020 Issue date: 28 Jun 2022 |
Grant Filling date: 16 Sep 2020 Issue date: 28 Jun 2022 |
Grant Utility: Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations Filling date: 28 Aug 2020 Issue date: 28 Jun 2022 |
Grant Filling date: 28 Jan 2019 Issue date: 28 Jun 2022 |
Application Filling date: 7 Mar 2022 Issue date: 16 Jun 2022 |
Grant Utility: TGF-beta inhibitors Filling date: 21 Mar 2019 Issue date: 7 Jun 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 7 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 5 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 7 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 1 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. David A. Santos (1963) Executive Vice President & Chief Commercial Officer | $1,030,000 |
| Mr. Raul R. Rodriguez (1961) Pres, Chief Executive Officer & Director | $971,120 |
| Ms. Dolly A. Vance (1965) Executive Vice President of Corporation Affairs, Gen. Counsel & Corporation Sec. | $734,710 |
| Dr. Wolfgang Dummer M.D., Ph.D. (1966) Executive Vice President & Chief Medical Officer | $614,360 |
Mr. Dean L. Schorno CPA (1963) Executive Vice President & Chief Financial Officer | $589,370 |
Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability
Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents
Rigel Pharmaceuticals: No Respect With Little Justification, Worth Considering A Buy
Rigel Pharmaceuticals: Push To Profitability Continues, But COVID Beacon Seems Extinguished
Rigel Pharmaceuticals Q1 Preview: A 2-Drug Company Pushing For Profitability
Rigel Pharmaceuticals: A Strong Finish To 2022 And A Potentially Transformative 2023
Rigel Pharmaceuticals Provides An Opportunity For Investors Or An Acquirer
argenx: A Very Good Start For Vyvgart
Rigel Pharmaceuticals: Why The Stock Is On A Run
-
What's the price of Rigel Pharmaceuticals stock today?
One share of Rigel Pharmaceuticals stock can currently be purchased for approximately $38.52.
-
When is Rigel Pharmaceuticals's next earnings date?
Unfortunately, Rigel Pharmaceuticals's (RIGL) next earnings date is currently unknown.
-
Does Rigel Pharmaceuticals pay dividends?
No, Rigel Pharmaceuticals does not pay dividends.
-
How much money does Rigel Pharmaceuticals make?
Rigel Pharmaceuticals has a market capitalization of 289.26M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 2.79% to 116.88M US dollars.
-
What is Rigel Pharmaceuticals's stock symbol?
Rigel Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "RIGL".
-
What is Rigel Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Rigel Pharmaceuticals?
Shares of Rigel Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Rigel Pharmaceuticals's key executives?
Rigel Pharmaceuticals's management team includes the following people:
- Mr. David A. Santos Executive Vice President & Chief Commercial Officer(age: 62, pay: $1,030,000)
- Mr. Raul R. Rodriguez Pres, Chief Executive Officer & Director(age: 64, pay: $971,120)
- Ms. Dolly A. Vance Executive Vice President of Corporation Affairs, Gen. Counsel & Corporation Sec.(age: 60, pay: $734,710)
- Dr. Wolfgang Dummer M.D., Ph.D. Executive Vice President & Chief Medical Officer(age: 59, pay: $614,360)
- Mr. Dean L. Schorno CPA Executive Vice President & Chief Financial Officer(age: 62, pay: $589,370)
-
How many employees does Rigel Pharmaceuticals have?
As Jul 2024, Rigel Pharmaceuticals employs 147 workers.
-
When Rigel Pharmaceuticals went public?
Rigel Pharmaceuticals, Inc. is publicly traded company for more then 24 years since IPO on 29 Nov 2000.
-
What is Rigel Pharmaceuticals's official website?
The official website for Rigel Pharmaceuticals is rigel.com.
-
Where are Rigel Pharmaceuticals's headquarters?
Rigel Pharmaceuticals is headquartered at 1180 Veterans Boulevard, South San Francisco, CA.
-
How can i contact Rigel Pharmaceuticals?
Rigel Pharmaceuticals's mailing address is 1180 Veterans Boulevard, South San Francisco, CA and company can be reached via phone at +65 06241100.
Rigel Pharmaceuticals company profile:
Rigel Pharmaceuticals, Inc.
rigel.comExchange:
NASDAQ
Full time employees:
147
Industry:
Biotechnology
Sector:
Healthcare
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
1180 Veterans Boulevard
South San Francisco, CA 94080
South San Francisco, CA 94080
CIK: 0001034842
ISIN: US7665596034
CUSIP: 766559603
